Back to Authors

Drake, Justin A.

0000-0002-2500-7044

A5042531131 | I160606119

Mayo Clinic

University of Tennessee Health Science Center

Citations 4

Perioperative Cyclooxygenase Inhibition and Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Systematic Review and Meta-analysis of Comparative Studies

Journal of the American College of Surgeons | April 17, 2023 | Volume: 236 | Issue: 5 | Pages: S65-S65

10.1097/01.xcs.0000932860.59570.50

Operative Efficiency of Thoracoabdominal Hepatectomy for Right-sided Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Journal of the American College of Surgeons | April 17, 2023 | Volume: 236 | Issue: 5 | Pages: S64-S65

10.1097/01.xcs.0000932852.89502.f6

Continuous Suture vs Interrupted Suture Duct-to-mucosa Pancreatojejunostomy After Pancreatoduodenectomy: A Systematic Review and Meta-analysis of Comparative Studies

Journal of the American College of Surgeons | April 17, 2023 | Volume: 236 | Issue: 5 | Pages: S59-S59

10.1097/01.xcs.0000932792.21130.bf

Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysis

Journal of Surgical Oncology | January 11, 2023 | Volume: 127 | Issue: 5 | Pages: 815-822

10.1002/jso.27198 | PMID 36629137

AbstractBackground and ObjectivesPublished data comparing peritoneal metastases from appendiceal cancers (pAC) and colorectal cancers (pCRC) remain sparse. We compared pAC and pCRC using comprehensive tumor profiling (CTP).MethodsCTP was performed, including next‐generation sequencing and analysis of copy number variation (CNV), microsatellite instability (MSI) and tumor mutational burden (TMB).ResultsOne hundred thirty‐six pAC and 348 pCRC samples underwent CTP. The cohorts' age and gender were similar. pCRC demonstrated increased pathogenic variants (PATHs) in APC (48% vs. 3%, p < 0.01), ARID1A (12% vs. 2%, p < 0.01), BRAF (12% vs. 2%, p < 0.01), FBXW7 (7% vs. 2%, p < 0.01), KRAS (52% vs. 41%, p < 0.05), PIK3CA (15% vs. 2%, p < 0.01), and TP53 (53% vs. 23%, p < 0.01), and decreased PATHs in GNAS (8% vs. 31%, p < 0.01). There was no difference in CNV, fusion rate, or MSI. Median TMB was higher in pCRC (5.8 vs. 5.0 mutations per megabase, p = 0.0007). Rates of TMB‐high tumors were similar (pAC 2.1% vs. pCRC 9.0%, p = 0.1957). pCRC had significantly more TMB‐high tumors at lower thresholds.ConclusionsDespite a reduced overall TMB, pAC demonstrated mutations distinct from those seen in pCRC. These may serve as discrete biomarkers for future study.